Compare · ADXS vs ANCN
ADXS vs ANCN
Side-by-side comparison of Advaxis, Inc. (ADXS) and Anchiano Therapeutics Ltd. (ANCN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ADXS and ANCN operate in Major Pharmaceuticals (Health Care), so they compete in similar markets.
- Company
- Advaxis, Inc.
- Anchiano Therapeutics Ltd.
- Price
- -
- -
- Market cap
- -
- -
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Major Pharmaceuticals
- Major Pharmaceuticals
- Exchange
- NASDAQ
- NASDAQ
- IPO
- n/a
- 2019
- News (4w)
- 0
- 0
- Recent ratings
- 0
- 0
Advaxis, Inc.
Advaxis, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of proprietary Listeria monocytogenes (Lm) technology antigen delivery products in the United States. The company is developing ADXS-PSA, which is in Phase 2 clinical trials for the treatment of metastatic prostate cancer; ADXS-503 that is in Phase 1/2 clinical trials for the treatment of non-small cell lung cancer; and ADXS-504 for the treatment of prostate cancer. It is also conducting clinical studies of Lm Technology immunotherapies in the following areas of disease focused hotspot/off-the-shelf neoantigen-directed therapies; human papilloma virus-associated cancers; and prostate cancer. The company has collaborations and partnerships with Merck & Co., Inc.; OS Therapies, LLC; Aratana Therapeutics Inc.; Biocon Limited; Global BioPharma Inc.; Knight Therapeutics Inc; and others. Advaxis, Inc. was founded in 2002 and is based in Monmouth Junction, New Jersey.
Latest ADXS
- OS Therapies Agrees to Acquire All Listeria Monotygenes-based Immuno-Oncology Programs and IP Assets from Ayala Pharmaceuticals, Adding Phase 2 Lung Cancer and Phase 1 Prostrate Cancer Programs to Pipeline
- Ayala Pharmaceuticals Files Form 15 to Voluntarily Deregister and Suspend its Reporting Obligations
- SEC Form 15-12G filed by Advaxis, Inc.
- SEC Form 10-K/A filed by Advaxis, Inc. (Amendment)
- Advaxis, Inc. filed SEC Form 8-K: Financial Statements and Exhibits (Amendment)
- SEC Form 10-K filed by Advaxis, Inc.
- SEC Form S-8 POS filed by Advaxis, Inc.
- SEC Form S-8 POS filed by Advaxis, Inc.
- SEC Form S-8 POS filed by Advaxis, Inc.
- SEC Form S-8 POS filed by Advaxis, Inc.
Latest ANCN
- SEC Form 8-K/A filed by Anchiano Therapeutics Ltd.
- SEC Form 4: Ltd. Gp Israel Orbimed was granted 288,170 units of American Depository Shares
- SEC Form 4: Peter Thiel bought $0 worth of American Depositary Shares (230,536 units at $0.00)
- SEC Form 3: Peter Thiel claimed ownership of 877,973 units of American Depositary Shares
- Anchiano Announces Shareholder Approval of the Merger with Chemomab and Prices $45.5M Private Financing
- SEC Form 4 filed by Stanislav Polovets
- SEC Form 3 filed by Stanislav Polovets
- SEC Form 3 filed by Andrew Fine
- SEC Form 4 filed by Harris Neil Cohen
- SEC Form 3: Harris Neil Cohen claimed ownership of 62,110 units of Ordinary Shares